Clinical trials: First Line Treatment
Lung Neoplasms
DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns
This is a prospective, observational, multicenter study, in which clinical and demographic data will be extracted from medical records.
- Trial name
- DeniLA (NCT07109154)
- Where
- 7 sites in Brazil
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Neonatal Abstinence Syndrome
Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy
The purpose of this study is to show non-inferiority between two medications used for medical treatment of withdrawal seen in Neonatal Abstinence Syndrome (NAS), Clonidine and Morphine Sulfate (used in routine care) on length of…
- Trial name
- NCT03092011
- Testing
- Clonidine, Morphine Sulfate
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- The Cooper Health System
Pilonidal Disease
Laser Hair Removal for Treatment of Pilonidal Disease
This project is a pilot study to determine if symptomatic pilonidal disease can be primarily managed with laser hair removal vs surgery.
- Trial name
- NCT03949140
- Testing
- Laser hair removal
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Wisconsin, Madison
Plasmodium Falciparum Malaria (Uncomplicated)
A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.
A partially blinded randomised controlled non-inferiority trial comparing the efficacy, tolerability and safety of Triple ACTs artemether-lumefantrine+amodiaquine (AL+AQ) and artesunate-mefloquine+piperaquine (ASMQ+PPQ) and the…
- Trial name
- DeTACT-Africa (NCT03923725)
- Testing
- Artemether-lumefantrine+ Amodiaquine (AL+AQ), Artesunate-mefloquine+piperaquine (AS-MQ+PPQ)
- Where
- 8 sites in Burkina Faso, Democratic Republic of the Congo and 6 more
- Volunteers
- 2,583 people
- Sponsor
- University of Oxford
Crohn Disease
Fecal Microbiota Transplantation as the First-line Treatment in Active Pediatric Crohn's Disease
To explore the safety and effectiveness of repeated and multiple fecal microbiota transplantations (FMTs) plus partial enteral nutrition (PEN) as a first-line treatment for active Crohn's disease (CD) in children.
- Trial name
- FMT (NCT05321758)
- Testing
- Fecal Microbiota Transplantation, Immunosuppressive Agents
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT01089088
- Testing
- cisplatin, gemcitabine hydrochloride, sunitinib malate
- Where
- 16 sites in United Kingdom
- Volunteers
- 63 people
- Sponsor
- Cardiff University
NSCLC (Advanced Non-small Cell Lung Cancer)
A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This is a Randomized, Double-Blind, Multicenter, Phase II/III Study to Evaluate HLX37 (Recombinant Human Anti-PD-L1 and Anti-VEGF Bispecific Antibody) in Combination with Chemotherapy Versus Pembrolizumab in Combination with…
- Trial name
- NCT07865910
- Testing
- Investigational drug: HLX37 dose1, IV, Q3W, PEMBROLIZUMAB (alone or when added to a regimen above), Carboplatin (Investigator discretion)
- Where
- 16 sites in China
- Volunteers
- 1,438 people
- Sponsor
- Shanghai Henlius Biotech
Rheumatoid Arthritis, Juvenile Idiopathic Arthritis
Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients
One of the main potential causes of these failures of BP therapy response is the development of Anti-drug Anti-body (ADAb) in some patients.
- Trial name
- ABI-RA (NCT02116504)
- Testing
- Sampling of blood
- Where
- France
- Volunteers
- 156 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hand Osteoarthritis
Outcomes After First-line Treatment of Hand Osteoarthritis
This study will investigate outcomes of a 3-month first-line treatment program for hand osteoarthritis, using data from the Swedish Osteoarthritis Registry.
- Trial name
- NCT07708454
- Testing
- 3 months of exercise and education
- Volunteers
- 2,000 people
- Sponsor
- Lund University
Malaria
In Vivo and in Vitro Efficacy of Antimalarial Treatments in Children in Burkina Faso
Resistance to antimalarial drugs represents a major obstacle for controlling malaria in endemic countries, so that most sub-Saharan countries have changed their antimalarial drug policy to the new Artemisinin Containing…
- Trial name
- NCT00808951
- Testing
- Artesunate-amodiaquine, Artemether-lumefantrine
- Where
- Burkina Faso
- Volunteers
- 440 people
- Sponsor
- Centre Muraz
C10.114.375.500
Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration
The study design matches with a multicenter observational ambispective study. A first pilot study will be undertaken in Caen center and is expected to be extended to Rouen and Lille center.
- Trial name
- PREMISEP (NCT03308994)
- Testing
- Delay between MS onset and introduction of first line DMT, EDI
- Where
- 4 sites in France
- Volunteers
- 650 people
- Sponsor
- University Hospital, Caen
Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Myelogenous Leukemia, Chronic, Chronic Phase
Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan
The purpose of this study is to evaluate effectiveness of Dasatinib as the first line therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase in Japan.
- Trial name
- D-First (NCT01464411)
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Kanto CML Study Group
Breast Cancer
BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer
Some chemotherapies, including docetaxel, are better tolerated and just as effective when giving the dose weekly rather than on an every three week basis.
- Trial name
- BREAST-10 (NCT00540800)
- Testing
- docetaxel, epirubicin, capecitabine
- Where
- 3 sites in Italy
- Volunteers
- 139 people
- Sponsor
- National Cancer Institute, Naples
In-stent Restenosis
Pilot Study of the Coronary Spur Stent for In-stent Restenosis (DEEPER CORONARY)
To demonstrate acceptable short term safety rates of the Drug-eluting Coronary Spur Stent System as a primary treatment for coronary in-stent restenosis.
- Trial name
- NCT06117150
- Testing
- Drug-eluting Coronary Spur Stent System
- Where
- 2 sites in New Zealand
- Volunteers
- 9 people
- Sponsor
- ReFlow Medical, Inc.
Breast Cancer
ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation.
The purpose of this study is to assess the difference in event-free survival between postmenopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued to…
- Trial name
- NCT00291759
- Testing
- Tamoxifen, Anastrozole
- Where
- 52 sites in Austria
- Volunteers
- 3,858 people
- Sponsor
- AstraZeneca
Acute Rhinosinusitis
Effectiveness and Safety of Once or Twice Daily Mometasone Nasal Spray Versus Amoxicillin Versus Placebo for Treatment of Acute Rhinosinusitis (Study P02683)
This study was conducted to compare the effectiveness and safety of mometasone nasal spray once daily or twice daily with amoxicillin or with placebo in treating the signs and symptoms of acute rhinosinusitis.
- Trial name
- NCT00750750
- Testing
- mometasone furoate nasal spray (MFNS), MFNS, Amoxicillin
- Volunteers
- 981 people
- Sponsor
- Organon and Co
NSCLC, Brain Metastasases
A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN)
A multicenter, single-arm, open-label study evaluating the safety and efficacy of AK112 combined with chemotherapy as first-line treatment for non-squamous NSCLC patients with BRAIN metastases and negative driver genes
- Trial name
- NCT06684873
- Testing
- AK112 Injection
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Sun Yat-sen University
Aspergillosis
Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis
This study compares the effectiveness and safety of the combination of anidulafungin and voriconazole compared to that of voriconazole alone (which is generally considered the standard of care) for the treatment of Invasive…
- Trial name
- NCT00531479
- Testing
- voriconazole, anidulafungin
- Where
- 107 sites in United States, Australia and 22 more
- Volunteers
- 459 people
- Sponsor
- Pfizer
Brain and Central Nervous System Tumors
Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002463
- Testing
- MOPP Regimen, Leucovorin Calcium, Mechlorethamine Hydrochloride
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Small Cell Lung Carcinoma
REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCER
Primary lung cancer is one of the most common malignancies and causes of cancer-related death worldwide [Passiglia et al., 2019; Bade and Dela Cruz, 2020].
- Trial name
- ARAL (NCT06826677)
- Testing
- Durvalumab
- Where
- 11 sites in Italy
- Volunteers
- 71 people
- Sponsor
- AstraZeneca